Ticker LaunchFiled, not priced · RKAM
ROKIT America, Inc.
ROKIT America, Inc. publicly filed a registration statement on Form S-1 on Apr 15, 2026 for a proposed initial public offering on Nasdaq under the ticker RKAM, and has not yet priced. Its latest amendment was filed on Jun 4, 2026. The filing shows a price range of $8.50–$10.50 per share. Underwriters named in the filing: Maxim Group.
ROKIT America, Inc. focuses on extending human healthspan through its proprietary Reverse Aging Product, intended to support cellular health, and an AI-driven Organ Regeneration Platform developed by its parent, ROKIT Healthcare, for regenerative medicine.
- Status
- Filed, not priced
- Ticker
- RKAM
- Exchange
- Nasdaq
- Price range
- $8.50–$10.50
- First filed
- Apr 15, 2026
- Latest amendment
- Jun 4, 2026
- Underwriters
- Maxim Group
- Sector
- Biotech & pharma
- Country / state
- CA
More on this listing for subscribers
- Shares offered, over-allotment and shares outstanding after the offering
- Amendment history
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Apr 15, 2026
- Latest amendment Jun 4, 2026
- All filings on EDGAR CIK 2087716
Other companies in the IPO pipeline
- MetaOptics LtdMay 4, 2026
- Tarsier Pharma Ltd.Apr 21, 2026
- Luvulis CorpApr 16, 2026
- Bravalo CorpApr 10, 2026
- Encore Inc.Apr 10, 2026
- TRIC Global, Inc.Apr 1, 2026